Idexx Laboratories [IDXX] vs Thermo Fisher [TMO] Detailed Stock Comparison
Idexx Laboratories
NASDAQ
Loading...
Thermo Fisher
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Idexx Laboratories wins in 8 metrics, Thermo Fisher wins in 11 metrics, with 0 ties. Thermo Fisher appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Idexx Laboratories | Thermo Fisher | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 51.08 | 26.89 | Thermo Fisher |
| Price-to-Book Ratio | 34.07 | 3.63 | Thermo Fisher |
| Debt-to-Equity Ratio | 84.81 | 69.62 | Thermo Fisher |
| PEG Ratio | 1.05 | 4.73 | Idexx Laboratories |
| EV/EBITDA | 37.47 | 19.60 | Thermo Fisher |
| Profit Margin (TTM) | 24.41% | 15.24% | Idexx Laboratories |
| Operating Margin (TTM) | 33.62% | 17.84% | Idexx Laboratories |
| EBITDA Margin (TTM) | 33.62% | 17.84% | Idexx Laboratories |
| Return on Equity | 64.87% | 13.42% | Idexx Laboratories |
| Return on Assets (TTM) | 23.26% | 4.97% | Idexx Laboratories |
| Free Cash Flow (TTM) | $798.08M | $7.27B | Thermo Fisher |
| Dividend Yield | N/A | 0.31% | N/A |
| 1-Year Return | 32.69% | -12.30% | Idexx Laboratories |
| Price-to-Sales Ratio (TTM) | 12.29 | 4.24 | Thermo Fisher |
| Enterprise Value | $52.19B | $212.08B | Thermo Fisher |
| EV/Revenue Ratio | 12.93 | 4.91 | Thermo Fisher |
| Gross Profit Margin (TTM) | 62.62% | 40.61% | Idexx Laboratories |
| Revenue per Share (TTM) | $50 | $114 | Thermo Fisher |
| Earnings per Share (Diluted) | $12.14 | $18.04 | Thermo Fisher |
| Beta (Stock Volatility) | 1.56 | 0.76 | Thermo Fisher |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Idexx Laboratories vs Thermo Fisher Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Idexx Laboratories | 2.21% | 2.53% | -0.88% | 16.79% | 48.70% | 55.03% |
| Thermo Fisher | -1.09% | 14.32% | 7.68% | 22.72% | 7.34% | 0.46% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Idexx Laboratories | 32.69% | 90.21% | 58.20% | 755.96% | 1,949.27% | 3,904.04% |
| Thermo Fisher | -12.30% | 0.26% | 12.97% | 314.92% | 1,006.11% | 1,622.87% |
News Based Sentiment: Idexx Laboratories vs Thermo Fisher
Idexx Laboratories
News based Sentiment: MIXED
IDEXX demonstrated continued strong financial performance and raised its long-term outlook, but insider selling and mixed institutional activity introduced some caution. The company's overall trajectory remains positive, but these factors warrant investor attention and monitoring as we approach the Q3 earnings report on October 30, 2025.
Thermo Fisher
News based Sentiment: POSITIVE
October 2025 was a demonstrably positive month for Thermo Fisher Scientific, characterized by a significant stock surge, strategic financial maneuvers, and proactive investments in innovation and customer support. These developments collectively reinforce a strong growth trajectory and positive investor sentiment.
Performance & Financial Health Analysis: Idexx Laboratories vs Thermo Fisher
| Metric | IDXX | TMO |
|---|---|---|
| Market Information | ||
| Market Cap | $49.74B | $201.36B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 409,804 | 2,827,260 |
| 90 Day Avg. Volume | 397,098 | 1,990,550 |
| Last Close | $633.84 | $524.96 |
| 52 Week Range | $356.14 - $688.12 | $385.46 - $616.57 |
| % from 52W High | -7.89% | -14.86% |
| All-Time High | $706.95 (Jul 26, 2021) | $672.34 (Dec 27, 2021) |
| % from All-Time High | -10.34% | -21.92% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.11% | 0.03% |
| Quarterly Earnings Growth | 0.45% | 0.05% |
| Financial Health | ||
| Profit Margin (TTM) | 0.24% | 0.15% |
| Operating Margin (TTM) | 0.34% | 0.18% |
| Return on Equity (TTM) | 0.65% | 0.13% |
| Debt to Equity (MRQ) | 84.81 | 69.62 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $18.20 | $133.77 |
| Cash per Share (MRQ) | $2.06 | $16.92 |
| Operating Cash Flow (TTM) | $905.81M | $7.58B |
| Levered Free Cash Flow (TTM) | $625.74M | $5.18B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.31% |
| Last 12-Month Dividend | N/A | $1.21 |
Valuation & Enterprise Metrics Analysis: Idexx Laboratories vs Thermo Fisher
| Metric | IDXX | TMO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 51.08 | 26.89 |
| Forward P/E | 51.85 | 20.65 |
| PEG Ratio | 1.05 | 4.73 |
| Price to Sales (TTM) | 12.29 | 4.24 |
| Price to Book (MRQ) | 34.07 | 3.63 |
| Market Capitalization | ||
| Market Capitalization | $49.74B | $201.36B |
| Enterprise Value | $52.19B | $212.08B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 12.93 | 4.91 |
| Enterprise to EBITDA | 37.47 | 19.60 |
| Risk & Other Metrics | ||
| Beta | 1.56 | 0.76 |
| Book Value per Share (MRQ) | $18.20 | $133.77 |
Financial Statements Comparison: Idexx Laboratories vs Thermo Fisher
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IDXX | TMO |
|---|---|---|
| Revenue/Sales | $998.43M | $10.36B |
| Cost of Goods Sold | $375.05M | $6.13B |
| Gross Profit | $623.38M | $4.24B |
| Research & Development | $59.06M | $342.00M |
| Operating Income (EBIT) | $316.53M | $1.82B |
| EBITDA | $351.81M | $2.73B |
| Pre-Tax Income | $310.08M | $1.62B |
| Income Tax | $67.41M | $95.00M |
| Net Income (Profit) | $242.68M | $1.51B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IDXX | TMO |
|---|---|---|
| Cash & Equivalents | $163.97M | $4.13B |
| Total Current Assets | $1.32B | $23.38B |
| Total Current Liabilities | $1.14B | $13.17B |
| Long-Term Debt | $546.80M | $31.37B |
| Total Shareholders Equity | $1.45B | $49.49B |
| Retained Earnings | $5.58B | $54.45B |
| Property, Plant & Equipment | $833.62M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IDXX | TMO |
|---|---|---|
| Operating Cash Flow | $235.07M | $2.15B |
| Capital Expenditures | $-30.03M | $-350.00M |
| Free Cash Flow | $207.94M | $361.00M |
| Debt Repayment | N/A | $-838.00M |
| Common Stock Repurchase | $-400.89M | $-2.00B |
Short Interest & Institutional Ownership Analysis
| Metric | IDXX | TMO |
|---|---|---|
| Shares Short | 2.12M | 3.83M |
| Short Ratio | 5.41 | 2.34 |
| Short % of Float | 0.03% | 0.01% |
| Average Daily Volume (10 Day) | 409,804 | 2,827,260 |
| Average Daily Volume (90 Day) | 397,098 | 1,990,550 |
| Shares Outstanding | 81.60M | 380.77M |
| Float Shares | 79.12M | 376.74M |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 0.97% | 0.92% |
Dividend Analysis & Yield Comparison: Idexx Laboratories vs Thermo Fisher
| Metric | IDXX | TMO |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.21 |
| Last 12-Month Dividend Yield | N/A | 0.31% |
| 3-Year Avg Annual Dividend | N/A | $1.33 |
| 3-Year Avg Dividend Yield | N/A | 0.07% |
| 3-Year Total Dividends | N/A | $3.99 |
| Ex-Dividend Date | N/A | Mar 14, 2025 |